Search | OpenScholar

Search results

1934 results found

Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. Lancet Neurol 2016;15:954-66.

Publication: Journal Article

Espay, AJ, PA LeWitt, RA Hauser, A Merola, M Masellis, and AE Lang. 2016. “Neurogenic Orthostatic Hypotension and Supine Hypertension in Parkinson’s Disease and Related Synucleinopathies: Prioritisation of Treatment Targets. Lancet Neurol 2016;15:954-66.”. Lancet Neurol.

Long-term effects of rasagiline and the natural history of treated Parkinson's disease. Mov Disord 2016;31:1489-1496.

Publication: Journal Article

Rascol, O, RA Hauser, F Stocchi, CJ Fitzer-Attas, Y Sidi, V Abler, CW Olanow, and AFU Investigators. 2016. “Long-Term Effects of Rasagiline and the Natural History of Treated Parkinson’s Disease. Mov Disord 2016;31:1489-1496.”. Mov Disord.

A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. Mov Disord 2016;31:1356-65.

Publication: Journal Article

LeWitt, PA, RA Hauser, DG Grosset, F Stocchi, MH Saint-Hilaire, A Ellenbogen, M Leinonen, et al. 2016. “A Randomized Trial of Inhaled Levodopa (CVT-301) for Motor Fluctuations in Parkinson’s Disease. Mov Disord 2016;31:1356-65.”. Mov Disord.

Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. Mov Disord 2016;31:709-14.

Publication: Journal Article

Weintraub, D, RA Hauser, V Abler, E Eyal, and RE Eliaz. 2016. “Rasagiline for Mild Cognitive Impairment in Parkinson’s Disease: A Placebo-Controlled Trial. Mov Disord 2016;31:709-14.”. Mov Disord.

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol 2016;73:102-110.

Publication: Journal Article

Investigators, Huntington Study Group PHAROS. 2016. “Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol 2016;73:102-110.”. JAMA Neurol.

How Should Pushing Off or the Use of Assistive Devices Be Incorporated in the Timed Up and Go for Persons With Parkinson Disease? Arch Phys Med Rehabil 2015;96:1728-32.

Publication: Journal Article

Stegemoller, EL, P Schmidt, , and National Parkinson Foundation Quality Improvement Initiative Investigators. 2015. “How Should Pushing Off or the Use of Assistive Devices Be Incorporated in the Timed Up and Go for Persons With Parkinson Disease? Arch Phys Med Rehabil 2015;96:1728-32.”. Arch Phys Med Rehabil .

Hauser RA. How to dose carbidopa and levodopa extended release capsules (Rytary). Clinical Medicine Journal 2015;1:34-7.

Publication: Journal Article

“Hauser RA. How to Dose Carbidopa and Levodopa Extended Release Capsules (Rytary). Clinical Medicine Journal 2015;1:34-7.”. 2015. Clinical Medicine Journal.

Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). Mov Disord 2015;30:788-95.

Publication: Journal Article

Pahwa, R, CM Tanner, RA Hauser, K Sethi, S Isaacson, D Truong, L Struck, et al. 2015. “Amantadine Extended Release for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASED Study). Mov Disord 2015;30:788-95.”. Mov Disord.

NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord 2015;30:1681-7.

Publication: Journal Article

O’Brien, CF, R Jimenez, RA Hauser, SA Factor, J Burke, D Mandri, and JC Castro-Gayol. 2015. “NBI-98854, a Selective Monoamine Transport Inhibitor for the Treatment of Tardive Dyskinesia: A Randomized, Double-Blind, Placebo-Controlled Study. Mov Disord 2015;30:1681-7.”. Mov Disord.

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. NINDS Exploratory Trials in Parkinson Disease (NET-PD). Lancet Neurol 2015;14:795-803.

Publication: Journal Article

Investigators, FS-ZONE. 2015. “Pioglitazone in Early Parkinson’s Disease: A Phase 2, Multicentre, Double-Blind, Randomised Trial. NINDS Exploratory Trials in Parkinson Disease (NET-PD). Lancet Neurol 2015;14:795-803.”. Lancet Neurol.